Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis ...
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. ( APGE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Gold Falls 1%; ProKidney Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday. The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39. Energy shares jumped by 2.1% on Tuesday.
Dow Dips 1%; Mustang Bio Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Artelo Biosciences ( NASDAQ:ARTL )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday. The Dow traded down 1% to 44,379.69 while the NASDAQ declined 0.85% to 20,426.99. The S&P 500 also fell, dropping, 0.39% to 6,255.16. Industrials shares jumped by 0.1% on Monday.
Top 2 Health Care Stocks That May Plunge This Month - Apogee Therapeutics ( NASDAQ:APGE ) , Phibro Animal Health ( NASDAQ:PAHC )
As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial - Apogee Therapeutics ( NASDAQ:APGE )
APG777 cut eczema severity by 71% at Week 16 vs. 33.8% for placebo; 66.9% reached EASI-75. Itch severity reduced by 50.7% within one week; APG777 was well tolerated with no safety concerns raised. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics ( NASDAQ:APGE ) , Apogee Enterprises ( NASDAQ:APOG )
Shares of Apogee Therapeutics, Inc. APGE rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week ...
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, July 06, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for the ...
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET Webcast to be held Monday, July 7th at 8:00 a.m. ET ...
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. ( APGE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, May 29, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Wall Street Analysts Think Apogee Therapeutics Inc. ( APGE ) Could Surge 132.72%: Read This Before Placing a Bet
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Apogee Therapeutics ( NASDAQ:APGE )
APG808 cut FeNO by 53% at week 12, with sustained 50% reduction, showing anti-inflammatory effect. No Grade 3 or severe adverse events; most common side effects included headache and mild injection reactions. Don't miss this list of 3 high-yield stocks-including one delivering over 10%-built for ...
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling ...
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of ...
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - Apogee Therapeutics ( NASDAQ:APGE )
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease ...
Wall Street Analysts Believe Apogee Therapeutics Inc. ( APGE ) Could Rally 134%: Here's is How to Trade
The mean of analysts' price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
SAN FRANCISCO and BOSTON, May 01, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T.
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - Apogee Therapeutics ( NASDAQ:APGE )
APG990's Phase 1 trial showed a 60-day half-life, supporting three- and six-month dosing. Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades ...
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule. topline Part A 16-week data expected ...
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 ( APG777 + APG990 )
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately ...
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET Webcast to be held Monday, March 3rd at 8:30 a.m. ET ...
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Conference Date: Tuesday, March 4, 2025 Time: 2:30 p.m. ET
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
SAN FRANCISCO and BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled ...
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of ...
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - Apogee Therapeutics ( NASDAQ:APGE )
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for ...
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, ...
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Apogee Therapeutics ( NASDAQ:APGE ) , ARM Holdings ( NASDAQ:ARM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Exane BNP Paribas analyst Kevin Grundy initiated coverage on Constellation Brands, Inc.
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for ...
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with ...
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, ...
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, ...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for ...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, ...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in ...
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to ...
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday - Methode Electronics ( NYSE:MEI )
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results.
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease ( COPD ) and other ...
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, ...
Apogee Therapeutics to Participate in Upcoming June Investor Conferences - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc.
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases ...
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - ARCA biopharma ( NASDAQ:ABIO )
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - ARCA biopharma ( NASDAQ:ABIO )
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Apogee ( APGE ) Stock Rallies 95.6% in a Month: Here's Why
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
